Colorectal Adenoma

Colorectal Neoplasm

Colorectal Cancer

Obesity

Metabolic Syndrome

Non-Alcoholic Fatty Liver Disease

Liver Fibrosis

All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.

Colonoscopy

South Tyneside NHS Foundation Trust

County Durham and Darlington NHS Foundation Trust

Kettering General Hospitals NHS Foundation Trust

The Leeds Teaching Hospitals NHS Trust

South Tees Hospitals NHS Foundation Trust

Northumbria Healthcare NHS Foundation Trust

Newcastle Upon Tyne NHS Foundation Trust

North Tees and Hartlepool NHS Foundation Trust

CIty Hospitals Sunderland NHS Foundation Trust

ObeSity Related Colorectal Adenoma Risk

Development of a risk model for colorectal adenoma or CRC based upon risk factors identified

Number of patients with colorectal adenomas or CRC who have abnormal liver enzymes

Number of patients with colorectal adenomas or CRC who are obese, as measured by BMI or waist circumference

Number of patients with colorectal adenomas or CRC who have abnormal FIB4 score

Number of patients with colorectal adenomas or CRC who have abnormal Fibroscan readings

Number of patients with colorectal adenomas or CRC who are smokers or have high alcohol intake

South Tyneside and Sunderland NHS Foundation Trust

Newcastle-upon-Tyne Hospitals NHS Trust

City Hospitals Sunderland NHS Foundation Trust

Kettering General Hospital NHS Foundation Trust

Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate

Hyperparathyroidism, Primary

Osteoporosis

During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).

cinacalcet

During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).

Alendronate

Istituto Auxologico Italiano IRCCS

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism

Maria Luisa Bianchi

M.D.

Istituto Auxologico Italiano

Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease

Für die Entwicklung neuer Biomarker mittels Massenspektrometrie werden 10ml EDTA-Blut und eine Filterkarte mit Trockenblutspots benötigt. Um die korrekte Diagnose für Glykogenosen bei den Patienten zu beweisen, bei denen bis zum Studieneinschluss noch keine genetische Diagnostik vorlag, werden die entsprechenden Sequenzierungen für den Nachweis der Glykogenosen erfolgen. Die Analysen werden von dem Labor Centogene AG pseudonymisiert durchgeführt. CENTOGENE AG Am Strande 7 18055 Rostock Germany

Fructose Metabolism, Inborn Errors

Glycogen Storage Disease

Glycogen Storage Disease Type I

Glycogen Storage Disease Type II

Glycogen Storage Disease Type III

Glycogen Storage Disease Type IV

Glycogen Storage Disease Type V

Glycogen Storage Disease Type VI

Glycogen Storage Disease Type VII

Glycogen Storage Disease Type VIII

Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.

Centogene AG

Amrita Institute of Medical Sciences & Research Centre

Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)

Lady Ridgeway Hospital for Children

Biomarker for Glycogen Storage Diseases (BioGlycogen)

Biomarker for Glycogen Storage Diseases - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

adenoma/phosphatase

ObeSity Related Colorectal Adenoma Risk

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

Biomarker for Glycogen Storage Diseases (BioGlycogen)

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen